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Objectives.We determined the activity of nitric oxide at rest and
after acetylcholine in the atherosclerotic human coronary circu-
lation.
Background. Although responses to acetylcholine, an
endothelium-dependent vasodilator, are abnormal in patients
with coronary atherosclerosis, whether this reflects abnormal
nitric oxide activity in humans in vivo has not been investigated
previously.
Methods. We investigated the effects of intracoronary L-NG-
monomethyl arginine (L-NMMA), a specific antagonist of nitric
oxide synthesis, on coronary vascular resistance and epicardial
coronary artery diameter at rest and after acetylcholine in 24
patients with coronary artery disease and in 12 subjects with
angiographically normal coronary arteries who were free from
atherosclerotic risk factors.
Results. With L-NMMA, the 13 6 4% (mean 6 SEM) increase
in coronary vascular resistance and the 4 6 1% lumen diameter
narrowing in atherosclerotic patients were lower than the 386 9%
increase in resistance and the 156 2% decrease in diameter (both
p < 0.01) observed in normal control subjects, indicating reduced
basal nitric oxide activity in atherosclerosis. The degree of angio-
graphic atherosclerotic narrowing did not correlate with the mag-
nitude of diameter reduction. Acetylcholine-induced coronary epi-
cardial and microvascular dilation was also depressed in
atherosclerotic patients (32.2 6 9% reduction in coronary vascu-
lar resistance with 1026 mol/liter acetylcholine) compared with
normal control subjects (65.5 6 2% decrease, p < 0.01). L-NMMA
inhibited acetylcholine-induced epicardial and microvascular va-
sodilation in both patient groups, but the inhibition was greater in
normal control subjects than in atherosclerotic patients, indicat-
ing that stimulation of nitric oxide activity by acetylcholine is
reduced in atherosclerotic patients compared with normal control
subjects. Coronary vascular dilation with sodium nitroprusside
was similar in both groups and was not suppressed by L-NMMA.
Furthermore, L-arginine reversed the constrictor effects of
L-NMMA, indicating that the action of L-NMMA is specifically
caused by inhibition of nitric oxide production from L-arginine.
Conclusions. These findings indicate that 1) there is a reduced
basal activity of nitric oxide in the human atherosclerotic epicar-
dial and microvascular coronary circulation; and 2) acetylcholine-
induced coronary vascular dilation is at least partly due to
stimulation of the activity of nitric oxide, and the reduced
response to acetylcholine is due to attenuation in the stimulated
activity of nitric oxide in patients with atherosclerosis.
(J Am Coll Cardiol 1997;29:308–17)
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The endothelium plays a pivotal role in determining vascular
tone by the tonic production of a variety of dilating and
constricting substances (1–4). Acetylcholine, a probe for re-
leasing endothelium-derived relaxing factor, dilates normal
smooth coronary arteries, whereas segments with either inti-
mal thickening or atherosclerosis constrict (5–10). However,
the response of atherosclerotic coronary arteries are not
uniformly abnormal with different endothelium-dependent va-
sodilators, suggesting that muscarinic receptor sensitivity in
atherosclerosis may, in part, account for the constrictor re-
sponses observed in atherosclerosis (11–13). Furthermore, in
some species, acetylcholine can stimulate release of not only
endothelium-derived relaxing factors, such as nitric oxide and
endothelium-derived hyperpolarizing factor (3), but also pros-
tacyclin (14) and endothelium-derived constricting factors
(15,16). The role of acetylcholine in stimulating nitric oxide
release from coronary arteries was further questioned in recent
animal and human studies where L-NG-monomethyl arginine
(L-NMMA) did not inhibit acetylcholine-induced coronary
vasodilation (17,18). In contrast to these findings, we have
demonstrated a significant role for endothelium-derived nitric
oxide in the normal human coronary vasculature (19). In this
study we tested the hypothesis that atherosclerosis is associated
with a diminished contribution of nitric oxide to in vivo basal
coronary vascular tone, and that the reduced vasodilator
response to acetylcholine in these patients is due to diminished
nitric oxide activity.
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Methods
Patients. We studied 36 patients, 24 with coronary athero-
sclerosis and 12 with angiographically normal coronary arter-
ies, who were undergoing diagnostic cardiac catheterization for
investigation of chest pain or abnormal noninvasive tests
(Table 1). Patients with valvular heart disease or those with
moderately severe left ventricular dysfunction (ejection frac-
tion ,35%) were excluded. Patients were selected as normal
control subjects if they had angiographically smooth epicardial
coronary arteries and were free from hypercholesterolemia
(cholesterol .250 mg/dl), hypertension or diabetes, and those
over the age of 60 years as well as recent or current smokers
were excluded. Results from nine of these control patients
have been reported in a previous study (19). Patients in the
normal control group were more often female, and by selec-
tion, were younger compared with the atherosclerotic group
(Table 1).
Measurements in patients with atherosclerosis were made
in coronary arteries with ,40% stenosis to ensure that micro-
vascular function could be measured. Of the 24 patients, only
5 had a 30% to 40% narrowed segment in the vessel where flow
was measured.
Protocol. All cardiac medications were withdrawn at least
48 h before the study, and aspirin or other cyclooxygenase
inhibitors were discontinued 7 days before. As reported previ-
ously (19), a 6F guide catheter was introduced into the
proximal segment of a coronary artery and blood flow velocity
was measured using a 0.018-in. (0.045-cm) wire equipped with
a Doppler crystal at its tip (Cardiometrics Flowire, Cardiomet-
rics, Inc.) (20). All drugs were infused directly into the left
main or right coronary artery (at half rate) through the guide
catheter at infusion rates ranging between 1 and 2 ml/min.
After 5 min of 5% dextrose infusion, endothelium-
dependent vasodilation was estimated by performing a dose-
response curve with incremental 2-min infusions of intracoro-
nary acetylcholine at 30, 100 and 300 mg/min (1026 mol/liter,
3.3 3 1026 mol/liter and 1025 mol/liter intracoronary concen-
trations). To prevent excessive constriction in atherosclerotic
patients, the dose-response curve was started at 3 mg/min
(1027 mol/liter). The dose of acetylcholine was not increased
further once the infusion either reduced blood flow velocity or
severely narrowed (.50%) the epicardial coronary tree. Thus,
19 atherosclerotic patients received the 30-mg/min dose and 12
received doses up to 100 mg/min. All normal control subjects
received doses up to 100 mg/min and two also received the
300-mg/min dose. Endothelium-independent function was es-
timated with 40 mg/min of sodium nitroprusside, and flow
reserve was measured with 2.2 mg/min of intracoronary aden-
osine.
After a 10-min interval, L-NMMA (Clinalfa, Switzerland), a
specific inhibitor of nitric oxide synthesis (21), was infused at
32 and 64 mmol/min for 5 min each. While continuing the
infusion of L-NMMA at 64 mmol/min, acetylcholine was read-
ministered at two doses that produced the highest flow velocity
response in 16 patients, and at the peak dilating dose in 6
patients with atherosclerosis. In normal control subjects, ace-
tylcholine was readministered at two doses that produced the
highest flow velocity response in seven patients, and at the
peak dilating dose in five patients. Thus, 11 atherosclerotic
patients received 3 mg/min, 19 patients received the 30-mg/min
dose and 7 received the 100-mg/min dose of acetylcholine
before and after L-NMMA. Twelve normal control subjects
received the 30-mg/min dose and seven the 100-mg/min dose of
acetylcholine before and after L-NMMA.
Twenty-three patients (15 atherosclerotic patients and 6
normal control subjects) had repeat infusions of 40 mg/min of
sodium nitroprusside for 3 to 4 min. Eleven individuals (8
patients with atherosclerosis and 3 normal control subjects)
were given 160 mmol/min of L-arginine for 10 min to test
whether the effects of L-NMMA were reversible. Blood flow
velocity was measured and coronary angiography was per-
formed after each intervention.
We have previously reported consistently reproducible cor-
onary vascular effects from two concurrent infusions of acetyl-
choline, sodium nitroprusside and adenosine (22). The study
was approved by the Institutional Review Board of the Na-
tional Heart, Lung, and Blood Institute.
Measurement of coronary blood flow and diameter. Coro-
nary blood flow was derived from the blood flow velocity and
diameter measurements using the formula (p 3 average peak
velocity 3 0.125 3 diameter2) (20). Coronary vascular resis-
tance was calculated as the mean arterial pressure/coronary
blood flow. For calculating flow, coronary artery diameter was
measured in a 0.5-cm segment of vessel beginning 0.25 cm
beyond the tip of the Flowire. Coronary angiograms were
recorded using a cineangiographic system (Toshiba, Inc.), and
quantitative angiography was performed with the ARTEK
software (Quantim 2001, Statview, ImageComm Systems,
Inc.).
Abbreviations and Acronyms
ANOVA 5 analysis of variance
L-NMMA 5 L-NG-monomethyl arginine









Male 18 2 0.01
Age (yr) 566 9 40 6 8 0.01
Age .60 yr 10 0 0.05
Total cholesterol (mg/dl) 2296 55 181 6 28 0.01
HDL cholesterol (mg/dl) 456 15 52 6 14 NS
Total cholesterol .240 mg/dl 8 0
Diabetes 9 0
Hypertension 11 0
Current smoking 7 0
Data presented are mean value 6 SEM or number of patients. HDL 5 high
density lipoprotein.
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In addition to the measurement of the diameter at the level
of the Doppler Flowire, 0.5- to 1-cm segments of mid and distal
regions of the epicardial coronary arteries were also measured
in all normal control subjects. In patients with atherosclerosis,
in addition to mid and distal segments, those that either
appeared to have plaque on the angiogram (,5% stenosis) or
were narrowed (range 5% to 50%) were measured during each
intervention by means of quantitative angiography. A total of
80 segments—24 that appeared angiographically smooth, 32
that had plaque, 16 producing 5% to 30% stenosis and 8 with
stenosis between 30% and 50%—were measured in patients
with atherosclerosis.
Statistical analysis. Data are expressed as mean value 6
SEM. Differences between means were compared by the
paired or unpaired Student t test, as appropriate. The effect of
L-NMMA on two doses of acetylcholine and the effects of two
doses of L-NMMA in normal control subjects and in athero-
sclerotic patients were compared by analysis of variance
(ANOVA) for repeated measures using a multiple regression
model that included dummy variables to correct for intersub-
ject variability (23). All p values were two-tailed, and a value
,0.05 was considered statistically significant. When the effects
of two doses of L-NMMA on coronary hemodynamic data were
compared with baseline values, a paired t test was performed
using a Bonferroni correction to alpha.
Results
Effect of L-NMMA on basal coronary vascular tone in
atherosclerosis. L-NMMA produced small increases in mean
arterial blood pressure in both groups; at the 32-mmol/min
dose of L-NMMA, arterial pressure was 3.4% higher in ath-
erosclerotic patients and 2.6% higher in normal control sub-
jects (both p , 0.01), and at the 64-mmol/min dose of
L-NMMA, it was 8.7% and 7.8% (both p , 0.01) higher,
respectively.
Coronary epicardial vessels. L-NMMA produced epicardial
coronary artery constriction in all patients, but at the highest
dose of L-NMMA, the mean diameter reduction of 3.7 6 1%
in atherosclerotic patients was significantly lower than the
15.6 6 2% decrease in normal control subjects (p , 0.01, Fig.
1). The magnitude of reduction in coronary diameter was
similar in the proximal, mid and distal segments in both
groups; thus, at the 64-mmol/min dose of L-NMMA, the
epicardial diameter constricted by 2.6 6 1.5%, 4.5 6 3% and
1.9 6 2% in the proximal, mid and distal segments in the
atherosclerotic patients (p 5 NS), and by 13.4 6 2.5%, 18.5 6
4% and 15.26 3%, respectively, in the normal control subjects
(p 5 NS).
There was no correlation between the angiographic severity
of coronary atherosclerosis and the effect of L-NMMA in
patients with atherosclerosis. Segments of epicardial coronary
arteries that appeared angiographically smooth, segments with
either mild plaque (,5% stenosis) or those with lesions
narrowing between 5% and 50% had similar effect with
L-NMMA (5.7%, 1.6% and 4.7% constriction, respectively).
All these segments constricted significantly less than in the
normal control subjects (p , 0.01).
Coronary microvasculature. L-NMMA produced an in-
crease in coronary vascular resistance in both groups, but the
13 6 4% increase in patients with atherosclerosis was signifi-
cantly less than the 38 6 9% increase in normal control
subjects (p , 0.01) at the highest dose of L-NMMA (Fig. 1).
Effect of L-NMMA on response to acetylcholine. Microvas-
cular vasodilation with acetylcholine occurred in both patient
groups, but was significantly depressed in patients with athero-
sclerosis at both the 30- and 100-mg/min doses (p , 0.001 by
ANOVA). Thus, at the 30-mg/min dose of acetylcholine,
coronary microvascular dilation was attenuated in patients
with atherosclerosis (32.26 9% reduction in coronary vascular
resistance) compared with normal control subjects (65.5 6 2%
decrease, p , 0.01) (Fig. 2). Similarly, epicardial coronary
arteries dilated by 5.3 6 4% (p , 0.03) in normal control
subjects, but there was no significant change (22 6 2.5%, p 5
NS) in patients with atherosclerosis (Fig. 2).
L-NMMA partially inhibited the microvascular dilation and
completely inhibited epicardial dilation with acetylcholine,
indicating that nitric oxide contributes to acetylcholine-
mediated vasodilation in both patient groups (Fig. 3). How-
ever, the effect of L-NMMA was greater in normal control
subjects compared with atherosclerotic patients. Thus, at the
30-mg/min dose of acetylcholine, there was significant inhibi-
tion of acetylcholine-mediated epicardial and microvascular
vasodilation in normal control subjects, but not in atheroscle-
rotic patients, so that the change in coronary diameter and
vascular resistance after L-NMMA was similar in both groups,
indicating that the greater effect of acetylcholine in normal
control subjects is due to higher nitric oxide activity in these
subjects compared with atherosclerotic patients (Fig. 2).
Effect of L-NMMA on response to sodium nitroprusside.
The effect of sodium nitroprusside on the epicardial coronary
artery segments and microvessels was similar in normal control
subjects and atherosclerotic patients: mean 17 6 2% increase
in diameter and 55 6 3% reduction in coronary vascular
resistance in normal subjects compared with 15 6 2% increase
in diameter and 50 6 3% reduction in resistance in athero-
sclerotic patients (p 5 NS, Fig. 4). In atherosclerotic patients,
smooth segments dilated by 19 6 5%, plaqued segments by
15 6 4.5% and stenotic segments (5% to 50% narrowing) by
11 6 3% with sodium nitroprusside. There was a trend toward
a significantly reduced dilation in stenotic segments compared
with segments in the normal control group (p , 0.08).
L-NMMA did not affect the epicardial or microvascular re-
sponse to sodium nitroprusside in either the atherosclerotic
patients or normal control subjects (Fig. 4).
Effect of adenosine in atherosclerotic and normal control
subjects. To ensure that the coronary artery narrowing in the
instrumented vessel was not limiting flow in patients with
atherosclerosis, we measured flow reserve with adenosine.
Coronary vascular resistance decreased by 68 6 2.5% in
atherosclerotic patients, and by 75 6 3% in normal control
subjects (p 5 NS).
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Effect of L-arginine on response to L-NMMA. To test the
specificity of L-NMMA, we examined the effect of L-arginine
on the response to L-NMMA at rest. The epicardial and
microvascular constriction with L-NMMA was reversed by
L-arginine (Fig. 5).
Impact of age and gender on responses to L-NMMA. To
rule out the possibility that the observed differences in nitric
oxide activity between normal control subjects and atheroscle-
rotic patients was due to differences in the age and gender
distribution in the two groups (Table 1), we analyzed sub-
groups matched for age and gender. With L-NMMA, the peak
increase in coronary vascular resistance was 34% in female
control patients (n 5 10) and 4 6 2.5% in atherosclerotic
women (n 5 6, p , 0.01). Similarly, epicardial coronary artery
segments constricted by 13.5 6 3% in female control patients
and by 1.2 6 2.5% in atherosclerotic women (p , 0.001).
We also compared responses in the 9 control subjects aged
35 to 55 years (mean 44) with 10 atherosclerotic patients in this
age range (mean 47 years). With 64 mmol/min of L-NMMA,
coronary vascular resistance increased by 36 6 8% in the
control subjects and by 15 6 7% in atherosclerotic patients
(p 5 0.05); patients with atherosclerosis who were aged .55
years also had a lower response compared with normal control
subjects (11 6 5% increase, p , 0.05), but the differences
between younger and older atherosclerotic patients was not
significant (p 5 0.6). Similarly, the reduction in epicardial
diameter with L-NMMA in control subjects aged 35 to 55 years
(214.2 6 3%) was significantly greater than the constriction in
atherosclerotic patients ,55 years of age (25.5 6 4%, p ,
0.001).
Discussion
There are three major findings of this study: 1) There is
reduced basal activity of nitric oxide in the atherosclerotic
epicardial and microvascular coronary circulation, indicated by
the reduced epicardial and microvascular constrictor effect of
L-NMMA in patients with atherosclerosis compared with nor-
mal control subjects. 2) Acetylcholine-induced epicardial and
coronary microvascular dilation is at least partly due to stim-
Figure 1. Changes in coronary vascular resistance,
blood flow and epicardial coronary artery diameter
with increasing concentrations of L-NMMA in ath-
erosclerotic patients and normal control subjects.
Data are presented as mean value 6 SEM. Com-
parison between the two patient groups was by
ANOVA. *p , 0.03, **p , 0.01, ***p , 0.002
compared with rest values.
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ulation of nitric oxide bioavailability because its effect is
attenuated by L-NMMA. 3) The depressed vasodilator re-
sponse to acetylcholine in patients with atherosclerosis is due
to reduced stimulated release of nitric oxide because of the
greater inhibition of acetylcholine-mediated vasodilation by
L-NMMA in normal control subjects compared with athero-
sclerotic patients.
That the excitatory function of the endothelium is abnormal
in atherosclerosis has been demonstrated by examining the
effects of intracoronary acetylcholine in human coronary arter-
ies in several previous studies (6–10,24–29). These investiga-
tions have shown constriction in atherosclerotic segments and
dilation in angiographically smooth segments. However, these
divergent responses to acetylcholine do not necessarily prove
diminished endothelium-derived nitric oxide availability in
atherosclerosis because acetylcholine may release not only
nitric oxide but also other endothelium-derived relaxing and
constricting factors (3,14–16). Thus, a constrictor response to
acetylcholine may be due to diminished release of non–nitric
oxide endothelium-derived relaxing factors or to stimulation of
constricting factor release. Alternatively, a constrictor re-
sponse to acetylcholine could indicate increased susceptibility
of the atherosclerotic smooth muscle to muscarinic receptor
stimulation despite normal relaxant factor release. Doubts
about the specificity of the effects of acetylcholine on the
endothelium are further supported by the observation that the
responses to substance P and acetylcholine were divergent in
the atherosclerotic human circulation in vivo, and L-NMMA
failed to inhibit the effects of acetylcholine in the normal
human coronary circulation (12,13,17). Our study was there-
fore designed to investigate both the basal activity of nitric
oxide and its stimulation with acetylcholine in human coronary
atherosclerosis in vivo.
Nitric oxide activity in human coronary atherosclerosis. A
variety of local, systemic and metabolic dilator and constrictor
stimuli modulate coronary vascular tone under rest conditions.
This study demonstrates that part of the dilator influence is
due to tonic activity of nitric oxide in the coronary epicardial
Figure 2. Impact of coronary atherosclerosis on the vas-
cular effects of acetylcholine before and after L-NMMA.
Coronary vascular resistance, blood flow and epicardial
coronary diameters with 30 mg/min of acetylcholine in 19
patients with atherosclerosis are compared with 12 normal
control subjects. †p , 0.05 and ††p , 0.01 denote
differences between rest value and after acetylcholine.
*p , 0.01 denotes differences between control acetylcho-
line and acetylcholine after L-NMMA. Results are shown
as mean value 6 SEM.
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arteries and microvessels in humans, and further, that this
contribution is reduced in patients with atherosclerosis. Even
smooth-appearing segments in patients with atherosclerosis
had reduced nitric oxide activity, and there was no correlation
between the angiographic severity of atherosclerosis (ranging
from minimal plaques to 50% stenosis) and the magnitude of
depression in basal nitric oxide activity. Thus, combined with
our previous observations demonstrating depressed nitric ox-
ide activity in coronary arteries of patients with angiographi-
cally normal coronary arteries but with several risk factors for
atherosclerosis (11,19), as well as observations made with
intravascular ultrasound (10), the findings of this study suggest
that abnormal nitric oxide activity in coronary arteries precedes
the development of angiographic atherosclerosis.
Despite the fact that atherosclerosis only affects epicardial
coronary arteries, it is clear from our findings that the dysfunc-
tion in bioavailability of nitric oxide extends beyond the
conductance vessels to the coronary microvessels. This is in
agreement with studies demonstrating abnormality in nitric
oxide activity in the microvessels of animals with hypercholes-
terolemia and atherosclerosis (30–33).
Although the results of our study demonstrate reduced
activity of nitric oxide in atherosclerosis, they do not allow us
to distinguish between the possible mechanisms of dysfunction
in the nitric oxide pathway. Among the proposed mechanisms
are 1) substrate deficiency, described in patients with hyper-
cholesterolemia (34,35); 2) reduced activity of nitric oxide
synthase; or 3) increased breakdown of normal or excessively
produced nitric oxide by reactive oxygen intermediates (36,37).
Further investigations are therefore warranted to clarify these
issues in human coronary atherosclerosis.
Acetylcholine-mediated nitric oxide activity in the coronary
vasculature in atherosclerosis. As previously reported in nor-
mal control subjects, acetylcholine-mediated microvascular
vasodilation was partially inhibited, and epicardial dilation
completely inhibited, by L-NMMA (19). This suggests that all
of the epicardial coronary dilation and part of the microvas-
cular dilation in response to acetylcholine are due to stimula-
tion of nitric oxide activity. These findings are important in
view of a previous study of patients with normal coronary
arteries, which failed to demonstrate inhibition of acetylcholine-
induced coronary vasodilation by L-NMMA (17). This may
have been either because a smaller and probably ineffective
dose of L-NMMAwas used or because coronary blood flow was
not directly measured. Also as previously reported, the re-
sponse of both epicardial and coronary microvessels to acetyl-
choline was depressed in patients with atherosclerosis (38).
This study demonstrates for the first time, in vivo in
humans, that acetylcholine enhances the activity of nitric oxide
in the microvessels of atherosclerotic patients, because its
Figure 3. Effects of increasing doses of intracoronary acetylcholine on
coronary vascular resistance, blood flow and percent change in epicar-
dial coronary artery diameter before and after L-NMMA in normal
control subjects (left) and atherosclerotic patients (right). Two vaso-
dilating doses of acetylcholine were reinfused after L-NMMA, and the
p values denote the results of ANOVA comparing the response to
acetylcholine before versus after L-NMMA. Results are shown as mean
value 6 SEM.
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effects were inhibited by L-NMMA. Because L-NMMA had a
greater inhibitory effect in normal control subjects than in
atherosclerotic patients, and because coronary vascular resis-
tance with acetylcholine after L-NMMA was similar in both
groups, it can be concluded that the depressed response to
acetylcholine in atherosclerosis is due to reduced activity of
nitric oxide.
Microvascular dilation with acetylcholine was not com-
pletely inhibited by L-NMMA in either patient group. This may
be due to incomplete inhibition of nitric oxide synthase by its
competitive antagonist L-NMMA, as the dose we could admin-
ister was limited by the systemic effects. Alternatively, it may be
due to a non–nitric oxide–mediated dilating action of acetyl-
choline (endothelium-derived hyperpolarizing factor and pros-
tacyclin) (3,14).
The magnitude of acetylcholine-induced microvascular di-
lation in atherosclerotic patients was similar to the dilation
observed in patients with risk factors and normal coronary
arteries in our previous investigation (19). This again empha-
sizes the fact that endothelial dysfunction of the coronary
vasculature, tested as its excitatory capacity with acetylcholine,
precedes the development of overt atherosclerosis, and is
presumably due to exposure to risk factors responsible for
atherosclerosis (28,39).
To overcome the concern that the atherosclerotic lesion in
the vessel being tested was not flow-limiting, we tested flow
reserve in all patients. Adenosine-induced microvascular vaso-
dilation was similar in atherosclerotic patients tested with
acetylcholine and in normal control patients and was greater
than the dilation observed with acetylcholine. Thus, we do not
believe that the limited vasodilation observed with acetylcho-
line in atherosclerotic patients was secondary to the epicardial
disease; instead, it is likely to truly represent the excitatory
dysfunction of the endothelium of the coronary microvessels.
Response to nitric oxide donors in atherosclerosis. That
the action of L-NMMA is specific for inhibition of L-arginine
metabolism was demonstrated by reversal of its effects by
L-arginine. In addition, the effects of sodium nitroprusside, an
Figure 4. Effect of L-NMMA on the changes in coronary
vascular resistance, blood flow and epicardial coronary
artery diameters with intracoronary sodium nitroprus-
side in normal control subjects and atherosclerotic pa-
tients. *p , 0.01 denotes differences between baseline
and sodium nitroprusside. There were no differences
between patients before and after L-NMMA. Results are
shown as mean value 6 SEM.
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endothelium-independent dilator, were not inhibited by
L-NMMA, indicating that the inhibitory effects of L-NMMA on
baseline coronary vascular resistance and on acetylcholine-
mediated vasodilation are due entirely to inhibition of synthe-
sis of nitric oxide. In patients with atherosclerosis, although the
dilator function of smooth segments and those with plaques
was preserved to the same extent with sodium nitroprusside as
that of segments in normal control subjects, the magnitude of
vasodilation in stenotic segments (5% to 50% narrowing) was
approximately two-thirds of that observed in normal control
subjects. This is believed to be partly due to either reduced rest
vasomotor tone in atherosclerosis or to disruption of the
smooth muscle layer that occurs with extensive atherosclerosis
(40). It should be emphasized, however, that the dilation in
response to sodium nitroprusside in stenotic segments was
much greater than the change observed with acetylcholine, so
the depressed response with acetylcholine cannot be attributed
to abnormal responsiveness of the vascular smooth muscle to
nitric oxide.
Potential study limitations. It can be argued that the
attenuated constriction with L-NMMA in atherosclerosis could
be a manifestation of differences in responsiveness to agonist
stimuli, and not to differences in nitric oxide activity. Two lines
of evidence argue against this possibility: animal (41) and
human studies using sympathetic stimuli have demonstrated
increased constriction at sites of atherosclerosis (28,42,43) with
up to 18% constriction with phenylephrine in the plaqued
segments of epicardial coronary arteries. Second, analysis of 36
segments that constricted with acetylcholine (mean 16% diam-
eter reduction, range 0% to 67%) revealed that the mean
constriction with L-NMMA was only 2.7% in these segments,
indicating that local hyporesponsiveness to all vasoconstrictor
stimuli was not the reason for the reduced effect of L-NMMA
in atherosclerosis.
There was mild systemic hypertension with L-NMMA,
which may have led to a baroreceptor-mediated withdrawal of
sympathetic tone. This, in turn, may have attenuated the
magnitude of L-NMMA–induced coronary vascular constric-
tion and resulted in an underestimation of the role of nitric
oxide on the coronary vascular tone.
Because previous studies have suggested that the function
of the endothelium may be affected by aging and gender
Figure 5. Effect of L-arginine on the coronary vascular effects
of L-NMMA at rest. Coronary vascular resistance, blood flow
and epicardial coronary diameters are compared at baseline,
after L-NMMA only and after L-NMMA and L-arginine. *p ,
0.05. **p , 0.01. Results are shown as mean value 6 SEM.
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differences (44,45), we examined the impact of atherosclerosis
in subgroups of patients who were matched for age and gender
and showed that the differences in normal control subjects and
atherosclerotic patients were not entirely due to the differences
in age and gender in these two groups.
Conclusions. This study demonstrates reduced bioavail-
ability of nitric oxide in the atherosclerotic human coronary
epicardial arteries and microvessels at rest and in response to
pharmacologic stimulation, which may predispose patients to
vasoconstriction, thrombosis and more rapid progression of
atherosclerosis.
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